New Viz.ai Study Demonstrates Reduced Mortality Rates in Patients with Pulmonary Embolism
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced clinical data validating the impact of the Viz PE Solution in the management and outcomes of patients with pulmonary embolism (PE).
- Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced clinical data validating the impact of the Viz PE Solution in the management and outcomes of patients with pulmonary embolism (PE).
- The data was presented during the 2024 AVF (American Venous Forum) by Jacob Shapiro, M.D., vascular surgeon at TriHealth in Cincinnati, OH.
- View the full release here: https://www.businesswire.com/news/home/20240307999862/en/
The real-world study, "Shorter Time to Assessment and Anticoagulation with Decreased Mortality in Patients with Pulmonary Embolism Following Implementation of Artificial Intelligence Software," evaluated the clinical impact of the Viz PE Solution on time to assessment, time to anticoagulation, and patient outcomes at TriHealth. - The study found that implementation of the AI-powered solution combined with PERT activation significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk.